2018-09-01 Bio Spectrum

Diseases Current Vaccine Status

Diarrhoea Rotavac- Developed by Bharat BiotechRotasil- Developed by Serum Institute of India

Diptheria

Pertussis

Tetanus

Hepatitis B

Haemophilus influenzae type b infection

Vaxtar 5- Developed by Indian Immnunologicals

Diptheria

Pertussis

Tetanus

Hepatitis B

Haemophilus influenzae type b infection

Polio

Easy Six- Developed by Panacea Biotech

Flu VaxiFlu-4 – Developed by Zydus Cadila

Typhoid Typbar TCV- Under development by Bharat Biotech

Chikungunya Under development by Bharat BiotechUnder development by Serum Institute of India

Rabies Rabishield- Developed by Serum Institute of India

Pneumonia Under development by Serum Institute of India

Dengue Under development by ICGEB in collaboration with Sun Pharma

Malaria

Under Development by Malaria Vaccine Development Programme

(MVDP)- a consortium of DBT, ICGEB, and PATH - Malaria Vaccine

Initiative, USA

(JAIVAC 2- Under toxicology assessment

JAIVAC 1- Completed phase I trial)

Tuberculosis rBCG- Under pre-clinical development (funding by DBT)

Cervical Cancer Under development by National Institute of Immunology (NII)- Currently in phase 2 trials

AIDS

Exploratory studies are being carried out at AIIMS in New Delhi,

Indian Institute of Science in Bengaluru, Translational Health Science

and Technology Institute in Faridabad, YR Gaitonde Centre for AIDS

Research and Education in Chennai, National Brain Research Centre in

Manesar, and International AIDS Vaccine Initiative (IAVI)

BIOSPECTRUM | SEPTEMBER 2018 | http://www.biospectrumindia.com COVER STORY^27

patented in 17 countries across
the world. This agreement with
Sun Pharma will help us to
produce the world’s first botanical
drug against dengue”, highlights
Dr Naveen Khanna, Senior
Scientist, ICGEB.
“Vaccine development
is not at all an easy
process. Challenges
surrounding vaccines are often specific to the vaccine
involved and can vary from a competitive landscape
to maintaining cold chain right upto the time of
administration and time-to-market since biological
products typically have shorter shelf life compared to
traditional pharma products. Vaccine manufacturing
has multiple challenges but companies should
continue to invest in finding solutions to ensure we
can supply life-saving vaccines produced at a high
quality while maintaining affordability”, explains

Dr Mahesh Bhalgat,

Executive Director and COO,

Shantha Biotechnics.

Another prominent player

in the vaccine market, Zydus

Cadila, has recently received

approvals from the Drug

Controller General of

India (DCGI), Central

Drugs Standard Control Organization (CDSCO)

and the Central Drug Laboratory (CDL) to market

its Tetravalent Inactivated Influenza vaccine for

seasonal flu, VaxiFlu - 4. With this, Zydus Cadila will

become the first Indian pharma company and second

in the world to launch a Tetravalent Inactivated

Influenza vaccine. The vaccine provides protection

from the four influenza viruses- H1N1, H3N2, Type B

(Brisbane) and Type B (Phuket).

“Disease prevention is the key to public health

in both the developing and the developed world

Current Vaccines R&D Scenario in India